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Low-dose clofarabine in combination with a standard
remission induction in patients aged 18-60 years
with previously untreated intermediate and bad-risk
acute myeloid leukemia or high-risk myelodysplastic
syndrome: combined phase I/II results of the
EORTC/GIMEMA AML-14A trial
The prognosis of younger patients with
intermediate/high risk acute myelogenous leukemia
(AML) or high-risk myelodysplastic syndromes (MDS)
remains unsatisfactory.1-4 Clofarabine is a purine nucleo-
side analog that is highly active as a single agent in AML.5
Furthermore, synergy between clofarabine and Ara-C has
been demonstrated in vitro6 and in AML patients.6-8 We
have recently reported the results of the randomized
phase I part of the EORTC/GIMEMA-AML-14A trial and
identified clofarabine at 10 mg/m2/day on days 2, 4, 6, 8
and 10 as the maximum tolerated dose (given either in a
1-hour infusion or as push injection) in combination with
Ara-C and idarubicin.9 We decided to administer clofara-
bine on these five days because we hypothesized that the
synergy between clofarabine and Ara-C would be more
effective when clofarabine was present in the leukemic
cells during the entire period of Ara-C administration.
Furthermore, we hypothesized that push injections of
clofarabine might result in higher clofarabine peak levels
than a 1-hour infusion schedule, leading to a better inter-
action with Ara-C and more pronounced anti-leukemic
effects. We  report the final results of the combined phase
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Table 1. Baseline patients’ characteristics.
Treatment arm
1-hour infusion Push injection Total 
(Arm A, n=31) (Arm B, n=31) (n=62)
Sex, n. of patients (%)
Male   16 (51.6) 11 (35.5) 27 (43.5)
Female 15 (48.4) 20 (64.5) 35 (56.5)
Age, years
Median 46.0 50.0 49.5
Range 20.0 - 60.0 22.0 - 60.0 20.0 - 60.0
Presence of poor prognosis featuresa at randomization, n. of patients (%) 6 (19.4) 5 (16.1) 11 (17.7)
WHO performance status, n. of patients (%)
0 23 (74.2) 23 (74.2) 46 (74.2)
1 7 (22.6) 7 (22.6) 14 (22.6)
2 1 (3.2) 1 (3.2) 2 (3.2)
WHO classification, n. of patients (%)
AML with multilineage dysplasia 5 (16.1) 6 (19.4) 11 (17.7)
AML therapy related 2 (6.5) 3 (9.7) 5 (8.1)
AML not otherwise specified 23 (74.2) 18 (58.1) 41 (66.1)
MDS RAEB II                                      1 (3.2) 4 (12.9) 5 (8.1)
Type of disease, n. of patients (%)
De novo AML or MDS                                              29 (93.5) 28 (90.3) 57 (91.9)
Secondary AML or MDS                                            2 (6.5) 3 (9.7) 5 (8.1)
WBC at diagnosis, n. of patients (%)
< 100 x109/L 27 (87.1) 30 (96.8) 57 (91.9)
≥ 100 x109/L 4 (12.9) 1 (3.2) 5 (8.1)
Cytogenetics,b n. of patients (%)
Normal 19 (61.3) 13 (41.5) 32 (51.6)
With FLT3-ITD and unmutated/unk NPM1 3 (9.7) 3 (9.7) 6 (9.7)
Without FLT3-ITD and with mutated NPMI 6 (19.4) 5 (16.1) 11 (17.7)
With FLT3-ITD and with mutated NPMI 3 (9.7) 1 (3.2) 4 (6.5)
Other or unknown molecular markers 7 (22.6) 4 (12.9) 11 (17.7)
Good risk 0 0 0
High risk 3 (9.7) 10 (32.3) 13 (21)
Very high risk 8 (25.8) 5 (16.1) 13 (21.0)
Unknown/ failure / missing 1c (3.2) 3 (9.7) 4 (6.5)
Bone marrow blasts (%)
Median 70 57 60.5
Range 19-97 12-99 12-99
aDefined as white blood cell count (WBC) at diagnosis ≥ 100x109/L or very high-risk cytogenetics or FLT3-ITD positivity; bcytogenetics: good risk includes inv(16) or t(8;21);
very bad risk includes complex abnormalitis (>3 abnormalities), monosomies 5, 7 and 5q-, 7q-, 3q, t(6;9), t(9;22), 11q23, t(9;11); bad risk includes all other chromosomal
abnormalities; c47,XY,dup(1)(q1?1q4?2),+8[7] / 46,XY,-17,+mar2[4] / 46,XY,-17,+mar1[3].  
I and II parts of the trial. 
EORTC/GIMEMA-AML-14A is an open label random-
ized 2-arm multicenter trial with a sequential phase I-II
design (clinicaltrials.gov identifier: 00838240). The protocol
was approved by the EORTC Protocol Review
Committee and by the Ethical Committee of each partic-
ipating center. The main objective of the phase II part of
the trial was to explore the anti-leukemic activity of the
aforementioned phase I selected dosage schedules of clo-
farabine given either as a 1-hour intravenous (iv) infusion
(Arm A) or as a push injection (Arm B) over ten minutes.
The primary end point was the complete remission
(CR)/CR with incomplete blood count recovery (CRi) rate
after 1 or 2 induction cycles. The aim was to determine
whether, in each treatment group, the true CR/CRi rate
was more than  65% or not. Thus, for each of the arms A
and B, the regimen was considered as active and feasible
if 23 or more of 30 (76.7%) patients achieved a CR/CRi
(see Online Supplementary Appendix for detailed study
design and methods of statistical analyses). Secondary
end points included toxicity, overall survival (OS) from
inclusion, OS from CR/CRi, relapse-free survival (RFS)
from CR/CRi, and incidences of relapse and of death in
CR/CRi. 
Inclusion criteria included: age 18-60 years, primary or
secondary intermediate or high-risk AML10 or MDS with
10%-19% blast cells in the bone marrow (BM), previous-
ly untreated disease, WHO Performance Status grade 0-2,
and adequate organ functions. Main exclusion criteria
included: good-risk AML (ie. AML-M3, or AML with
t(8;21) or inv(16)) and a white blood cell count (WBC) at
diagnosis of less than 100x109/L), blast crisis chronic
myeloid leukemia or AML supervening a myeloprolifera-
tive disorder, central nervous system leukemia, evidence
of severe concurrent cardiac, pulmonary, and neurologi-
cal disorder, and uncontrolled infection. 
Clofarabine was administered at 10 mg/m2 on days 2,
4, 6, 8 and 10 either as a 1-hour infusion (Arm A) or as a
push injection (Arm B). Ara-C was administered at 100
mg/m2/day on days 1-10 as a continuous infusion, while
idarubicin was given at 10 mg/m2/day on days 1, 3, and 5
as a 5-minute iv injection. A second identical course of
induction chemotherapy was given in case of a partial
response (PR). One cycle of consolidation chemotherapy
consisting of Ara-C (500 mg/m2 every 12 hours as a 
2-hour iv infusion on days 1-6) and idarubicin (10
mg/m2/day on days 4, 5 and 6) was administered in
patients in both arms who achieved a CR/CRi. Post-con-
solidation treatment was left at the discretion of the local
principal investigator, but it was recommended that the
consolidation phase was followed by allogeneic
hematopoietic cell transplantation (HCT) for patients
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Figure 1. Overall survival (A), relapse-free survival from complete remission (CR) (B), cumulative incidence of relapse from CR (C) and cumulative incidence of
death in CR (D) in the two arms.
A B
C D
with an HLA-identical related donor or for patients with
very high-risk cytogenetics who had an HLA-compatible
related or unrelated donor, or an autologous HCT in
patients who were not candidates for allogeneic HCT.1
A total of 64 patients (12 in the phase I part and 52 in
the phase II part of the study) were randomized at the
dosage of clofarabine of 10 mg/m2/day (Online
Supplementary Figure S1). Two patients were excluded
because they did not meet the inclusion criteria. Among
the remaining 62 patients, 41 had AML not otherwise
specified, 11 AML with multilineage dysplasia, 5 therapy-
related AML while 5 patients were diagnosed with MDS-
RAEB2. Median age was 49.5 (range 20-60) years.
Baseline characteristics were generally well balanced
between the two arms (Table 1). 
After one induction course, the CR/CRi rates were 26
of 31 patients in arm A (84%) versus 25 of 31 patients in
arm B (80%) (Table 2). The CR/CRi rate after 1 or 2
induction courses was 84% (95%CI: 66%-95%), in both
arms, higher than the protocol-defined efficacy (>65%)
(Table 2). Interestingly, combining the results from both
arms, the CR/CRi rate after 1 or 2 courses of induction
was similar in patients with very high-risk cytogenetics
[11 of 13 patients (84.6%)], and in patients with normal
or high-risk cytogenetics [38 of 46 patients (82.6%)].
These results are in the same range as those observed in
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Table 2. Disease response (primary end point) and adverse events.
Treatment arm
1-hour infusion Push injection Total 
(Arm A, n=31) (Arm B, n=31) (n=62)
Responsea to induction n.1, n. of patients (%)
CR 23 (74.2)  24 (77.4) 47 (75.8)
CRi 3 (9.7) 1 (3.2) 4 (6.5)
PR 1 (3.2) 1 (3.2) 2 (3.2)
Failure due to resistant disease 0 (0.0) 4 (12.9) 4 (6.5)
Failure due to complication from aplasia 2 (6.5) 1 (3.2) 3 (4.8)
Hypoplasia 1 (3.2) 0 (0.0) 1 (1.6)
Not assessable 1 (3.2) 0 (0.0) 1 (1.6)
Response to inductions n.1 / 2, n. of patients (%)
CR 23 (74.2) 25 (80.6) 48 (77.4)
CRi 3 (9.7) 1 (3.2) 4 (6.5)
PR 1 (3.2) 0 (0.0) 1 (1.6)
Failure due to resistant disease 0 (0.0) 4 (12.9) 4 (6.5)
Failure due to complication from aplasia 2 (6.5) 1 (3.2) 3 (4.8)
Hypoplasia 1 (3.2) 0 (0.0) 1 (1.6)
Not assessable 1 (3.2) 0 (0.0) 1 (1.6)
Most frequent (>5% in at least one arm) grade III-IVb biochemical abnormalities, n. of patients (%)
Bilirubin 4 (12.9) 6 (19.4) 10 (16.1)
ALT 4 (12.9) 4 (12.9) 8 (12.9)
Alkaline phosphatase 0 2 (6.5) 2 (3.2)
Most frequent (>5% in at least one arm) grade III-IVb adverse events, n. of patients (%)
Febrile neutropenia 23 (74.2) 13 (41.9) 36 (58.1)
Documented infection 13 (42.0) 22 (70.9) 35 (56.5)
Anorexia 6 (19.4) 10 (32.3) 16 (25.8)
Diarrhea 7 (22.6) 6 (19.4) 13 (21.0)
Dyspnea 3 (9.7) 1 (3.2) 4 (6.5)
Fatigue 1 (3.2) 2 (6.5) 3 (4.8)
Rash 3 (9.7) 1 (3.2) 4 (6.5)
Nausea 2 (6.5) 1 (3.2) 3 (4.8)
Hemorrhage 3 (9.7) 0 3 (4.8)
Deshydratation 0 2 (6.5) 2 (3.2)
Documented grade II-IV fungal infection, n. of patients (%) 4 (12.9) 9 (29.0) 13 (21.0)
Causes of death
Acute myeloid leukemia 4 (12.9) 4 (12.9) 8 (12.9)
Toxicity 4 (12.9) 1 (3.2) 5 (8.1)
Transplant-related mortality 7 (22.6) 5 (16.1) 12 (19.4)
Other 0 1 (3.2) 1 (1.6)
aEvaluation of response was scheduled around day 31 after the start of the induction course. CR was defined as less than 5% marrow blasts and recovery of normal
hematopoiesis with a neutrophil count ≥ 1x109/L and a platelet count ≥ 100x109/L in addition to disappearance of all clinical, laboratory, or radiological evidence of disease.
The term incomplete CR (CRi) was used to define patients who met all CR criteria, but had neutrophil counts between 0.5 and 1.0x109/L and/or platelet counts between
50 and 100x109/L. Finally, partial remission (PR) was defined as 5%-25% blast cells in the bone marrow and a reduction of at least 50% of blasts in the bone marrow, irrespec-
tive of count recovery.  bAdverse events were graded with Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scoring system
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf). 
two recent phase II studies investigating the efficacy of
higher dosages of clofarabine combined with AraC (and
idarubicin) as remission induction regimen for younger
AML patients.11,12
With a median follow up of 1.8 (range 1-5.3) years, 15
of 31 (48%) patients in arm A and 11 of 31 patients
(36%) in arm B died. One-year OS from inclusion was
74% (95%CI: 55%-86%) in each arm, while median sur-
vival was 2.5 (1 not reached) years in arm A, versus not
yet reached in arm B (Figure 1A). 
Consolidation chemotherapy was given in all of 26
patients who achieved a CR/CRi in arm A, and in 23 of
26 patients (88.5%) in arm B. Following consolidation
chemotherapy, 12 of 26 patients in arm A received an
allogeneic HCT, while, in arm B, 14 patients received an
allogeneic HCT and 2 an autologous HCT. Among a total
of 52 patients in CR/CRi, 1-year OS and RFS from
CR/CRi were 77% (95%CI: 56%-89%) and 58%
(95%CI: 37%-74%), respectively, in arm A versus 73%
(95%CI: 51%-86%) and 65% (95%CI: 44%-80%),
respectively, in arm B (Figure 1B). One-year incidences of
relapse and of death in CR were 23% (95%CI: 7%-39%)
and 19% (95%CI: 4-34%), respectively, in arm A, versus
19% (95%CI: 4%-34%) and 15% (95%CI: 2-29%),
respectively, in arm B (Figure 1C and D). As expected, the
incidence of relapse was higher in CR/CRi patients with
very high risk cytogenetics (5 of 11: 45%) than in those
with intermediate-/high-risk cytogenetics (10 of 38:
26%).
The toxicity profile of the two tested remission-induc-
tion chemotherapy regimens was acceptable and compa-
rable in the two arms (Table 2), confirming data observed
in the phase I of our study.9 Median time to neutrophils
of  0.5x109/L or more and of 1.0 x109/L or more were 28
(range 22-96) and 31 (range 22-99+) days, respectively, in
arm A, versus 27 (range 20-50) and 29 (range 21-50) days,
respectively, in arm B (Table 2). Further, median time to
platelet levels  of 20x109/L or more or of  100x109/L or
more were 28 (range 24-83) and 31.5 (range 24-99+)
days, respectively, in arm A, versus 27 (range 23-44) and
31 (range 24-51) days, respectively, in arm B. Besides
hematologic recovery, the toxicities over grade 2
observed in the AML-14A patients were in the same
range as currently observed after standard remission-
induction chemotherapy, with the possible exception of a
higher incidence of over grade 2 hyperbilirubinemia that
was observed in 18% of the AML-14A patients.
We finally compared the outcomes of the AML14A
patients to those of a subgroup of 201 patients from the
standard arm of the previous EORTC/GIMEMA-AML-12
study (combining standard dose Ara-C, daunorubicin and
etoposide; see Online Supplementary Appendix)1 who met
the same inclusion criteria as current patients, and were
treated in the centers that contributed patients to the cur-
rent AML14A study. As shown in the Online
Supplementary Table S1,  patients' characteristics were
comparable in the 2 groups. However, since these analy-
ses were not planned beforehand in the protocol, they
should be seen as indicative. The rate of CR/CRi after 1
or 1-2 cycles of induction chemotherapy were 82.3% and
83.9%, respectively, in current AML14A patients versus
66.7% and 72.6%, respectively in the cohort of AML12
patients (Online Supplementary Table S2). A higher propor-
tion of patients included in the AML-14A (50%) than in
AML-12 (30%) were offered an allogeneic HCT, probably
reflecting, at least in part, the higher CR/CRi rate
achieved in AML-14A patients. One-year OS and RFS
rates were 74.1% (95%CI: 61.3%-83.3%) and 61.5%
(95%CI: 47.0%-73.2%), respectively, in current AML14
patients, and 58.0% (95%CI: 50.9%-64.5%) and 54.1%
(95%CI: 45.7%-61.8%), respectively, in AML12 patients.
Finally, among patients who reached a CR, the 1-year
cumulative incidences of relapse and of death in CR were
23.3% and 17.3%, respectively, in AML-14A, as com-
pared with 37.7% and 9.6%, respectively, in AML-12. 
In conclusion, the two tested clofarabine containing
regimens yielded an impressive CR/CRi rate and encour-
aging 1-year OS/RFS rates among patients with interme-
diate/high-risk AML or high-risk MDS. These results are
worth confirming in a large phase III study.
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